Special, Practical Considerations When Employing Oral Factor Xa Inhibitors in Patients with VTE: Bridging Therapy, Switching from VKAs to NOAC-Based Treatment, Cancer-Related VTE, Optimizing Bleeding Risk Reduction, and Patient Preference Issues - Professor The Lord Ajay Kakkar, BSc, PhD, FRCS